Results 71 to 80 of about 2,680 (134)
Background Preeclampsia (PE), a serious obstetric complication impacting maternal and fetal health, still lacks reliable biomarkers owing to limited sensitivity, specificity, and disease heterogeneity.Methods Differentially expressed genes (DEGs) were ...
Chunzi Xu +5 more
doaj +1 more source
Genetic and phenotypic characterization of Parkinson’s disease at the clinic-wide level
Observational studies in Parkinson’s disease (PD) deeply characterize relatively small numbers of participants. The Molecular Integration in Neurological Diagnosis Initiative seeks to characterize molecular and clinical features of every PD patient at ...
Thomas F. Tropea +27 more
doaj +1 more source
A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. [PDF]
den Heijer JM +22 more
europepmc +1 more source
The glucocerebrosidase (GCase) encoded by the GBA1 gene hydrolyzes glucosylceramide (GluCer) to ceramide and glucose in lysosomes. Homozygous or compound heterozygous GBA1 mutations cause the lysosomal storage disease Gaucher disease (GD) due to severe ...
Myung Jong Kim +3 more
doaj +1 more source
Given the established association between numerous GBA1 variants and specific neurological diseases, we extended the exploration by a phenome-wide association study to assess the impact of GBA1 variants on a wider spectrum of health-related traits.
Jiaqi Yang +15 more
doaj +1 more source
Background Gaucher disease (GD) is one of the most common types of lysosomal storage diseases (LSDs) caused by pathogenic variants of lysosomal β-glucocerebrosidase gene (GBA1), resulting in the impairment of Glucocerebrosidase (GCase) enzyme function ...
Keatdamrong Janpipatkul +15 more
doaj +1 more source
Loss-of-function mutations in the GBA1 gene are a prevalent risk factor for Parkinson’s disease (PD). Defining features are Lewy bodies that can be rich in α-synuclein (αS), vesicle membranes, and other lipid membranes, coupled with striatal dopamine ...
Silke Nuber +17 more
doaj +1 more source
Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson's disease. [PDF]
Kwatra M, Kwak G, Li H, Suk JS, Ko HS.
europepmc +1 more source
Acid β-glucosidase (GBA1) gene mutational spectrum and clinical phenotypes in patients with gaucher disease: seven novel mutations in a multicenter retrospective cohort study from upper Egypt. [PDF]
Youssef MAM +5 more
europepmc +1 more source

